Mercadolibre Inc vs GeneDx Holdings Corp — how do they compare? Mercadolibre Inc trades at $1,873.18 (market cap $94.13B), while GeneDx Holdings Corp trades at $67.82 (market cap $2.02B). The key difference: Mercadolibre Inc is far larger — about 46.6× GeneDx Holdings Corp's market cap, and Mercadolibre Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and GeneDx Holdings Corp for 19 Days on average.
| MELI | WGS | |
|---|---|---|
Market Cap | $94.13B | $2.02B |
Volume | 273,781 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $167.51 |
52-Week Low | $1.55K | $34.51 |
Typical Hold Time | 117 Days | 19 Days |
Enterprise Value | $101.77B | $2.05B |
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,868.01, down 0.25% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $28.89 billion in 2025, though net income margin compressed to 6.91%. Recent news highlights expansion in Brazil's delivery and pharmacy segments, while analyst consensus remains strongly bullish with a $2,170 price target.
MELI's integrated e-commerce and fintech ecosystem in Latin America presents significant growth potential, supported by expanding credit portfolios and advertising revenue. Key risks include macroeconomic pressures in Argentina and margin compression from increased investment. With 73% analyst buy ratings and institutional accumulation, the stock offers growth exposure but requires monitoring of profitability trends.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →